



NEWS RELEASE

SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting

11/3/2022

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- **SELLAS Life Sciences Group, Inc.** (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present data relating to its highly selective CDK9 inhibitor, GFH009, during two poster presentations at the American Society of Hematology (ASH) Annual Meeting being held on December 10-13, 2022 in New Orleans, Louisiana. The meeting will also take place virtually.

During the first poster presentation, SELLAS will share data related to GFH009's mechanism of action associated anti-proliferative activity in various hematologic malignancies. The second poster presentation highlights preliminary safety and efficacy data from the first-in-human study of GFH009 in patients with relapsed / refractory hematologic malignancies.

Additional presentation details can be found below:

Title: " In Vitro and In Vivo Studies Support GFH009, a Selective CDK9 Inhibitor, As a Potential Treatment for Hematologic Cancers "

Abstract #: 3477

Session Name: 802. Chemical Biology and Experimental Therapeutics: Poster II

Date/Time: Sunday, December 11, 2022 at 6:00 PM CT

Location: Ernest N. Morial Convention Center, Hall D

Presenter: Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS

Title: " First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies "

Abstract #: 4263

Session Name: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III

Date/Time: Monday, December 12, 2022 at 6:00 PM CT

Location: Ernest N. Morial Convention Center, Hall D

Presenter: Dr. Siyuan Le of GenFleet

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as "plan," "expect," "anticipate," "may," "might," "will," "should," "project," "believe," "estimate," "predict," "potential," "intend," or "continue" and other words or terms of similar meaning. These statements include, without limitation, statements related to the preclinical and clinical development of GFH009, including the potential for GFH009 as a drug development candidate. These forward-looking statements

are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company's clinical plans and business strategy, risks and uncertainties associated with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption "Risk Factors" in SELLAS' Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact

Allison Soss

KCSA Strategic Communications

Email: **SELLAS@kcsa.com**

Phone: 212.896.1267

Media Contacts

Raquel Cona / Michaela Fawcett

KCSA Strategic Communications

Email: **SELLAS@kcsa.com**

Phone: 212.896.1276

Source: SELLAS Life Sciences Group, Inc.